Moreover, homozygous and heterozygous mutations in Triggering Receptor Expressed on Myeloid cells 2 (TREM2) may resemble FTD clinical phenotype without any bone-associated symptoms [11, 12]. This evidence concerns the gene TREM2 and frontotemporal dementia.